US20190336598A1 - Methods for modulating inflammasome activity and inflammation in the lung - Google Patents
Methods for modulating inflammasome activity and inflammation in the lung Download PDFInfo
- Publication number
- US20190336598A1 US20190336598A1 US16/474,708 US201716474708A US2019336598A1 US 20190336598 A1 US20190336598 A1 US 20190336598A1 US 201716474708 A US201716474708 A US 201716474708A US 2019336598 A1 US2019336598 A1 US 2019336598A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- inflammasome
- asc
- aim2
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- EV from TBI mice induced alveolar morphological changes (decreased alveolar size) and infiltration of inflammatory cells as determined by H&E staining ( FIG. 7G ).
- ALI score is significantly increased in EV delivered from injured mice compared to uninjured mice ( FIG. 7H ).
- binding fragments include: (i) an Fab fragment consisting of VL, VH, CL and CH1 domains (Ward, E. S. et al., (1989) Nature 341, 544-546); (ii) an Fd fragment consisting of the VH and CH1 domains (McCafferty et al., (1990) Nature, 348, 552-554); (iii) an Fv fragment consisting of the VL and VH domains of a single antibody (Holt et al., (2003) Trends in Biotechnology 21, 484-490); (iv) a dAb fragment (Ward, E. S.
- NALP1 and NLRP1 mean an expression product of an NALP or NLRP1 gene or isoforms; or a protein that shares at least 65% (but preferably 75, 80, 85, 90, 95, 96, 97, 98, or 99%) amino acid sequence identity with NALP (e.g., accession number(s) AAH51787, NP_001028225, NP_127500, NP_127499, NP_127497, NP055737) and displays a functional activity of NALP1.
- accession number(s) AAH51787, NP_001028225, NP_127500, NP_127499, NP_127497, NP055737 displays a functional activity of NALP1.
- Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof
- a hybridoma producing a monoclonal antibody of the present invention may be cultivated in vitro, in situ or in vivo.
- this Example showed that AIM2 inflammasome signaling plays a central role in the pathomechanism of lung injury after TBI and demonstrates a mechanism of TBI-induced ALI involving EV-mediated inflammasome signaling.
- EV-mediated inflammasome signaling can play a central role involving a Neuronal-Respiratory-Inflammatory Axis. Therefore, targeting this axis with antibodies against inflammasome proteins or drugs that block EV uptake may provide a therapeutic approach in Neurotrauma-induced ALI in all areas of critical care medicine.
- the disclosed therapeutic strategies may be useful for the treatment of inflammatory diseases of the lung in general.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/474,708 US20190336598A1 (en) | 2016-12-29 | 2017-12-28 | Methods for modulating inflammasome activity and inflammation in the lung |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662440180P | 2016-12-29 | 2016-12-29 | |
US16/474,708 US20190336598A1 (en) | 2016-12-29 | 2017-12-28 | Methods for modulating inflammasome activity and inflammation in the lung |
PCT/US2017/068713 WO2018126009A1 (fr) | 2016-12-29 | 2017-12-28 | Méthode visant à moduler l'activité de l'inflammasome et l'inflammation dans le poumon |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/068713 A-371-Of-International WO2018126009A1 (fr) | 2016-12-29 | 2017-12-28 | Méthode visant à moduler l'activité de l'inflammasome et l'inflammation dans le poumon |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/358,582 Continuation US20210324065A1 (en) | 2016-12-29 | 2021-06-25 | Methods for modulating inflammasome activity and inflammation in the lung |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190336598A1 true US20190336598A1 (en) | 2019-11-07 |
Family
ID=62710025
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/474,708 Abandoned US20190336598A1 (en) | 2016-12-29 | 2017-12-28 | Methods for modulating inflammasome activity and inflammation in the lung |
US16/026,482 Active US10703811B2 (en) | 2016-12-29 | 2018-07-03 | Methods and compositions for treating multiple sclerosis |
US16/847,054 Active US10961306B2 (en) | 2016-12-29 | 2020-04-13 | Methods for treating lung inflammation with an anti-ASC antibody |
US16/856,407 Active US11174307B2 (en) | 2016-12-29 | 2020-04-23 | Methods and compositions for treating virus-associated inflammation |
US17/358,582 Abandoned US20210324065A1 (en) | 2016-12-29 | 2021-06-25 | Methods for modulating inflammasome activity and inflammation in the lung |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/026,482 Active US10703811B2 (en) | 2016-12-29 | 2018-07-03 | Methods and compositions for treating multiple sclerosis |
US16/847,054 Active US10961306B2 (en) | 2016-12-29 | 2020-04-13 | Methods for treating lung inflammation with an anti-ASC antibody |
US16/856,407 Active US11174307B2 (en) | 2016-12-29 | 2020-04-23 | Methods and compositions for treating virus-associated inflammation |
US17/358,582 Abandoned US20210324065A1 (en) | 2016-12-29 | 2021-06-25 | Methods for modulating inflammasome activity and inflammation in the lung |
Country Status (15)
Country | Link |
---|---|
US (5) | US20190336598A1 (fr) |
EP (2) | EP3562506A4 (fr) |
JP (3) | JP2020503345A (fr) |
KR (1) | KR20200013630A (fr) |
CN (1) | CN110461356A (fr) |
AU (1) | AU2017386550A1 (fr) |
BR (1) | BR112019013463A2 (fr) |
CA (2) | CA3048864A1 (fr) |
CO (1) | CO2019008087A2 (fr) |
IL (1) | IL267685A (fr) |
MX (1) | MX2019007916A (fr) |
PH (1) | PH12019501549A1 (fr) |
RU (1) | RU2019123160A (fr) |
SG (1) | SG10202106385XA (fr) |
WO (2) | WO2018126009A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10703811B2 (en) | 2016-12-29 | 2020-07-07 | University Of Miami | Methods and compositions for treating multiple sclerosis |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021222263A2 (fr) * | 2020-04-27 | 2021-11-04 | University Of Miami | Compositions et méthodes pour le traitement de maladies ou de troubles liés aux inflammasomes |
JP2021528092A (ja) * | 2018-07-03 | 2021-10-21 | ユニバーシティ オブ マイアミ | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
WO2021097084A1 (fr) * | 2019-11-12 | 2021-05-20 | The Uab Research Foundation | Procédés de traitement de l'immunosuppression et de maladies associées à l'immunosuppression |
CN111363847B (zh) * | 2020-02-12 | 2021-06-29 | 广州微远医疗器械有限公司 | 基于CRISPR技术的2019-nCoV快速检测引物组及其用途 |
CN113278730B (zh) * | 2020-02-20 | 2022-03-25 | 中元汇吉生物技术股份有限公司 | 一种新型冠状病毒检测试剂盒、用途及其使用方法 |
US20230172933A1 (en) * | 2020-03-19 | 2023-06-08 | Nanyang Technological University | Use of a compound or composition comprising an inhibitor of nlrp1 inflammasome activation for the treatment of human airway inflammation |
CN111289745A (zh) * | 2020-03-25 | 2020-06-16 | 中山生物工程有限公司 | 新型冠状病毒IgM抗体酶联免疫检测试剂盒及其检测方法 |
KR102658146B1 (ko) * | 2020-03-26 | 2024-04-18 | 경북대학교 산학협력단 | Pannexin3을 포함하는 근육 손상 진단용 바이오마커 조성물 및 이를 이용한 진단방법 |
CN111529707B (zh) * | 2020-04-29 | 2021-04-23 | 威海市立医院 | Gsdmd抑制剂在制备治疗幽门螺杆菌感染的药物中的应用 |
CN111777684A (zh) * | 2020-06-09 | 2020-10-16 | 重庆君同生物技术有限公司 | 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用 |
KR102582417B1 (ko) * | 2020-11-06 | 2023-09-26 | 한국과학기술원 | 인플라마솜 어댑터 단백질(asc)의 중합체화 도메인에 결합하는 신규한 폴리펩타이드 및 이의 용도 |
CN113109569B (zh) * | 2021-03-05 | 2022-08-19 | 李朴 | Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途 |
KR102673132B1 (ko) * | 2021-04-20 | 2024-06-12 | 아주대학교산학협력단 | 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드 |
US20230027739A1 (en) | 2021-05-10 | 2023-01-26 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
AU2022335541A1 (en) * | 2021-08-25 | 2024-02-01 | R.P. Scherer Technologies, Llc | Antibodies having humanized framework regions |
CN115819548B (zh) * | 2021-11-16 | 2023-09-01 | 北京美德泰康生物科技有限公司 | 一种检测炎症相关疾病的标志物和方法 |
WO2024006457A1 (fr) * | 2022-06-29 | 2024-01-04 | University Of South Florida | Méthode de traitement de maladies neurologiques induites par un covid long |
WO2024114906A1 (fr) | 2022-11-30 | 2024-06-06 | Mabylon Ag | Anticorps dirigés contre une protéine de type speck associée à l'apoptose contenant une card (asc) et leurs utilisations |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
KR101194446B1 (ko) | 2004-04-29 | 2012-10-24 | 오쓰까 세이야꾸 가부시키가이샤 | 당단백 vi에 특이적인 항체 및 그의 제조방법 |
KR20070094890A (ko) | 2004-10-25 | 2007-09-27 | 머크 앤드 캄파니 인코포레이티드 | 안티 addl 항체 및 그 용도 |
TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
RU2009135824A (ru) | 2007-02-27 | 2011-04-10 | Дженентек, Инк. (Us) | Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний |
WO2009014863A2 (fr) * | 2007-06-29 | 2009-01-29 | Thomas Jefferson University | Asc et pyroptosomes pyrine-asc, et utilisations de ceux-ci |
US8685400B2 (en) | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
WO2010003092A1 (fr) * | 2008-07-03 | 2010-01-07 | University Of Massachusetts | Procédés et compositions pour réduire une inflammation et traiter des troubles inflammatoires |
EP2475380A1 (fr) * | 2009-09-11 | 2012-07-18 | Protaffin Biotechnologie AG | Composition destinée au traitement de l'inflammation pulmonaire à médiation par cxcl8 |
ES2773031T3 (es) | 2010-05-14 | 2020-07-09 | Amgen Inc | Formulaciones de anticuerpos anti-esclerostina a alta concentración |
IT1406201B1 (it) | 2010-12-10 | 2014-02-14 | Univ Degli Studi Trieste | Biomarcatori per la diagnosi della sclerosi multipla |
EP2684051B1 (fr) | 2011-03-11 | 2016-04-27 | Roche Diagniostics GmbH | Asc en tant que marqueur pour la maladie pulmonaire obstructive chronique (copd) |
EP2812697B1 (fr) | 2012-02-06 | 2017-03-22 | University of Miami | Protéines immunitaires innées comme biomarqueurs pour une lésion du snc |
TWI480044B (zh) | 2012-03-16 | 2015-04-11 | Taichung Veterans General Hospital | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution |
US20140314746A1 (en) * | 2013-03-13 | 2014-10-23 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma |
BR112015028338A2 (pt) * | 2013-05-17 | 2017-07-25 | Genentech Inc | métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal |
JP6359013B2 (ja) * | 2013-07-29 | 2018-07-18 | 国立大学法人 鹿児島大学 | 1,5−d−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
JP7066321B2 (ja) * | 2014-01-10 | 2022-05-13 | アヴァリン ファーマ インク. | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 |
EP3183582B1 (fr) | 2014-08-18 | 2020-02-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Biomarqueurs pour le diagnostic et le suivi de maladies neuro-immunologiques |
US20160263183A1 (en) | 2015-03-10 | 2016-09-15 | Brown University | Methods for treating lung disease |
JP7372026B2 (ja) * | 2015-05-12 | 2023-10-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 炎症および線維症のペプチド治療 |
MX2018002049A (es) | 2015-08-17 | 2018-06-15 | Twi Biotechnology Inc | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. |
KR101948048B1 (ko) | 2016-12-08 | 2019-02-14 | 한양대학교 에리카산학협력단 | 톡소포자충 gra7 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물 |
RU2019123160A (ru) | 2016-12-29 | 2021-01-29 | Юниверсити Оф Майами | Способ модуляции активности инфламмасом и воспаления в легком |
MX2020003079A (es) | 2017-09-20 | 2021-01-08 | Univ Miami | Método para detectar proteínas inflamasoma como biomarcadores de trastornos neurológicos. |
JP2021528092A (ja) | 2018-07-03 | 2021-10-21 | ユニバーシティ オブ マイアミ | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
-
2017
- 2017-12-28 RU RU2019123160A patent/RU2019123160A/ru unknown
- 2017-12-28 KR KR1020197022320A patent/KR20200013630A/ko not_active Application Discontinuation
- 2017-12-28 JP JP2019536086A patent/JP2020503345A/ja active Pending
- 2017-12-28 CA CA3048864A patent/CA3048864A1/fr active Pending
- 2017-12-28 US US16/474,708 patent/US20190336598A1/en not_active Abandoned
- 2017-12-28 AU AU2017386550A patent/AU2017386550A1/en active Pending
- 2017-12-28 EP EP17888678.4A patent/EP3562506A4/fr not_active Withdrawn
- 2017-12-28 CN CN201780087090.4A patent/CN110461356A/zh active Pending
- 2017-12-28 WO PCT/US2017/068713 patent/WO2018126009A1/fr unknown
- 2017-12-28 SG SG10202106385XA patent/SG10202106385XA/en unknown
- 2017-12-28 MX MX2019007916A patent/MX2019007916A/es unknown
- 2017-12-28 BR BR112019013463-8A patent/BR112019013463A2/pt unknown
-
2018
- 2018-07-03 US US16/026,482 patent/US10703811B2/en active Active
-
2019
- 2019-06-26 IL IL267685A patent/IL267685A/en unknown
- 2019-07-01 PH PH12019501549A patent/PH12019501549A1/en unknown
- 2019-07-25 CO CONC2019/0008087A patent/CO2019008087A2/es unknown
-
2020
- 2020-04-13 US US16/847,054 patent/US10961306B2/en active Active
- 2020-04-23 US US16/856,407 patent/US11174307B2/en active Active
-
2021
- 2021-04-23 EP EP21792075.0A patent/EP4139348A2/fr active Pending
- 2021-04-23 WO PCT/US2021/028847 patent/WO2021217004A2/fr unknown
- 2021-04-23 JP JP2022564482A patent/JP2023515271A/ja active Pending
- 2021-04-23 CA CA3176518A patent/CA3176518A1/fr active Pending
- 2021-06-25 US US17/358,582 patent/US20210324065A1/en not_active Abandoned
-
2022
- 2022-11-11 JP JP2022181180A patent/JP2023016835A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10703811B2 (en) | 2016-12-29 | 2020-07-07 | University Of Miami | Methods and compositions for treating multiple sclerosis |
US10961306B2 (en) | 2016-12-29 | 2021-03-30 | University Of Miami | Methods for treating lung inflammation with an anti-ASC antibody |
US11174307B2 (en) | 2016-12-29 | 2021-11-16 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
Also Published As
Publication number | Publication date |
---|---|
RU2019123160A (ru) | 2021-01-29 |
US20200308262A1 (en) | 2020-10-01 |
WO2021217004A3 (fr) | 2021-12-16 |
CN110461356A (zh) | 2019-11-15 |
JP2020503345A (ja) | 2020-01-30 |
US10703811B2 (en) | 2020-07-07 |
KR20200013630A (ko) | 2020-02-07 |
EP3562506A1 (fr) | 2019-11-06 |
CA3048864A1 (fr) | 2018-07-05 |
US10961306B2 (en) | 2021-03-30 |
US20190002550A1 (en) | 2019-01-03 |
RU2019123160A3 (fr) | 2021-01-29 |
EP4139348A2 (fr) | 2023-03-01 |
BR112019013463A2 (pt) | 2020-01-07 |
JP2023515271A (ja) | 2023-04-12 |
PH12019501549A1 (en) | 2020-02-24 |
MX2019007916A (es) | 2019-12-05 |
AU2017386550A1 (en) | 2019-08-08 |
WO2018126009A1 (fr) | 2018-07-05 |
SG10202106385XA (en) | 2021-07-29 |
JP2023016835A (ja) | 2023-02-02 |
US20200347124A1 (en) | 2020-11-05 |
CA3176518A1 (fr) | 2021-10-28 |
US20210324065A1 (en) | 2021-10-21 |
US11174307B2 (en) | 2021-11-16 |
IL267685A (en) | 2019-08-29 |
CO2019008087A2 (es) | 2019-10-21 |
EP3562506A4 (fr) | 2021-01-06 |
WO2021217004A2 (fr) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210324065A1 (en) | Methods for modulating inflammasome activity and inflammation in the lung | |
US20210284723A1 (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
JP2021006543A (ja) | 好酸球又はマスト細胞関連障害の治療 | |
US20220153826A1 (en) | Methods and compositions for treating virus-associated inflammation | |
US20230340091A1 (en) | Antibodies for the treatment of synucleinopathies and neuroinflammation | |
US20230238030A1 (en) | Methods for modulating inflammasome activity and inflammation in the lung | |
US20090155204A1 (en) | Methods for treating disorders involving monocytes | |
US20220372159A1 (en) | Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damages | |
TW202033558A (zh) | 化膿性汗腺炎治療中使用的抗cd40抗體 | |
US20240124570A1 (en) | Inflammasome antibody compositon and method for treating neurologic disorder | |
WO2024055015A1 (fr) | Composition d'anticorps anti-inflammasome et méthode de traitement d'un trouble neurologique | |
NZ755639A (en) | Method for modulating inflammasome activity and inflammation in the lung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF MIAMI SCHOOL OF MEDICINE;REEL/FRAME:053701/0118 Effective date: 20200827 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MIAMI, UNIVERSITY OF;REEL/FRAME:064987/0249 Effective date: 20200903 |